

Author Index
Volume 50
July—December 1994

- Abas, N., 383
 Abu, K.A., 391
 Achedume, A.C., 391
 Adepoju, A.Y., 391
 Aedo, A-R, 87
 Affandi, B., 477
 Ahmed, Y., 263
 Akhter, H., 263
 Alcazar, L.S., 401
 Alfonso, L., 417
 Amatya, R., 17, 263, 339, 349, 417
 Appelman, Z., 239
 Au, C.L., 477
 Aydinlik, S., 329
 Bachman, G.A., 109
 Ballagh, S.A., 517, 535
 Ballon, R., 401
 Beijing Collaborating Study Group for Ec-
 topic Pregnancy, 253
 Bernstein, G.S., 319
 Bernstein, L., 319
 Betancourt, J.D., 417
 Blumenthal, P.D., 451
 Bocchinfuso, W.P., 301
 Cachrimanidou, A-C, 153
 Carranza-Lira, S., 401
 Cekan, S.Z., 87
 Chabra, S., 185
 Chakraborty, N., 363
 Cheng, L-n, 501
 Chi, I-c, 339, 409
 Coelingh Bennink, H.J.T., 373
 Colditz, G.A., 1
 Coulson, A.H., 319
 Creinin, M., 511
 Crona, N., 153
 Cui, Y., 253
 Dabancens, A., 243
 Dacalos, E., 417
 Daniel, S., 77
 David, M., 417
 Désaulniers, G., 229
 Diaz-Flores, M., 581
 Dieben, ThOM, 373
 Doncel, G., 185
 Drouin, J., 229
 Du, Ming-kin, 501
 Du, Mingkun, 27
 Dunson, T.R., 349
 Duran-Reyes, G., 581
 Ecavade, A., 175
 Eggena, P., 517, 535
 Etchepareborda, J.J., 329
 Family Health International, 1S
 Farr, G., 17, 339, 417
 Frezieres, R., 319
 Gabbay, L., 551
 Garg, S., 185
 Gates, D., 263
 Grimes, D.A., 319
 Gu, S., 27
 Guerrero, A., 243
 Guilbert, E.E., 229
 Hammond, G.L., 301
 Hankinson, S., 1
 Haspels, A.A., 101
 Haukkamaa, M., 275
 Heikinheimo, O., 275
 Hellberg, D., 153
 Hamberger, L., 143
 Hicks, J.J., 581
 Hopton, C., 77
 Huggins, G.R., 451
 Indian Council of Medical Research Task
 Force on IUD and Hormonal
 Contraceptives, 215
 IUD Study Group, 319
 Ingelhammar, E., 143
 Insler, V., 239
 Jackanicz, T.M., 517, 535
 Jiang, X., 131
 Jin, X., 253
 Jing, X., 253
 Johannisson, E., 87
 Johnson, J.A., 383
 Jütting, G., 563
 Katz, Z., 239

- Kawachi, I., 1
 Kesserü, E.v., 329
 Knuppel, R.A., 109
 Koivunen, D.G., 383
 Krueger, S.L., 349
 Kuhn, W., 563
 Lacarra, M., 517, 535
 Lähteenmaki, P., 275
 Landgren, B-M, 87
 Latin America Oral Contraceptive Study Group, 215
 Lavill, K., 117
 Levy, R., 239
 Li, H., 131
 Li, Y., 491
 Lian, S., 253
 Lilya, H., 143
 Lin, D., 131
 Liu, Y., 27
 Lu, Y-l, 501
 Lurie, S., 239
 Madeley, R., 77
 McCann, M.F., 15
 McMahan, J., 263
 Merino, G., 401
 Mishell, D.R., Jr., 517, 535
 Möller, A., 143
 Moran, C., 401
 New Zealand Contraception and Health Study Group, 431, 443
 Pasquale, S.A., 109
 Pearson, J., 77
 Peplow, P.V., 69
 Nilsson, S., 153
 Noe, G., 275
 Nwoha, P.U., 391
 Orava, M., 301
 Owens, A.G., 109
 Painter, R., 167
 Petta, C.A., 17, 339
 Potter, L.S., 15
 Potts, M., 551
 Premakumara, G.A.S., 291
 Rao, A.R., 175
 Ratnasooriya, W.D., 291
 Rogers, P.A.W., 477
 Remsburg, R.E., 451
 Sang, G-w, 501
 Seigbahn, A., 153
 Shafik, A., 191
 Shao, Q-x, 501
 Shen, Q., 131
 Shoupe, D., 535
 Sivin, I., 27
 Smith, C.L., 301
 Sparrow, M.J., 117
 Svanberg, B., 143
 Talwar, G.P., 185
 Theeuwes, A., 373
 Tillekeratne, L.M.V., 291
 Törnblom, M., 143
 Ullah, M.S., 363
 Upadhyay, S.N., 185
 van den Ende, A., 301
 van Enk, A., 301
 Vessey, M., 167
 von Schoultz, B., 153
 Vromans, L., 373
 World Health Organization Task Force for Epidemiological Research on Reproductive Health, 35, 55
 World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation, 461
 Walsh, T.L., 319
 Wang, Qing-Yun, 491
 Wang, Suhua, 27
 Wang, Zhong-Shan, 491
 Weng, Li-ju, 501
 Weng, Liju, 253
 Williamson, N., 263
 Wilson, S., 77
 Wu, X-Z, 501
 Zhang, Linde, 27
 Zhang, Liying, 253
 Zhang, Zhiyan, 253
 Zhang, Zhongshu, 131
 Zhang, Zhuomin, 253
 Zhao, Dan, 491
 Zhao, Lin-Yang, 491
 Zhao, Xue-Jian, 491
 Zipper, J., 243

Subject Index
Volume 50
July—December 1994

- Abortion applicants, contraceptive use experience, 143
- Acceptability, NORPLANT® implants, 349
- Acne,
 - effect of ethinylestradiol + cyproterone acetate, 373
 - effect of ethinylestradiol + desogestrel, 373
- Adolescents, contraceptive use, 451
- Antibiotics, effect on IUD insertion, 319
- Antineoplastic activity, quinacrine and copper (mouse), 243
- Barrier contraceptive, Lea's Shield®, 551
- Benefits and risks, fertility control methods, 1
- Biochemical studies, effect of gossypol (rat), 391
- Bioself fertility indicator, 229
- Blood pressure, effect of hormonal contraceptives, 131
- Breakage and slippage, condoms, 117
- Breastfeeding, effect of progestin-only pills, S13A
- Cancer risk, progestin-only pills, S72
- Cardiovascular disease risk, progestin-only pills, S64
- Cervical dysplasia risk,
 - use of contraceptive methods, 431
 - use of depot-medroxyprogesterone acetate, 443
- Cervix, effect of RU 486, 461
- Conception rates, impact of teenage contraceptive clinic, 77
- Condoms,
 - benefits and risks, 1
 - breakage and slippage, 117
- Contraceptive aid, Bioself device, 229
- Contraceptive methods, risk of cervical dysplasia, 431
- Contraceptive use,
 - adolescents, 451
 - experience in abortion applicants, 143
 - relationship to ectopic pregnancy, 253
- Contraceptive vaginal ring, releasing ethinyl estradiol + norethindrone acetate, 517, 535
- Copper and quinacrine, antineoplastic activity (mouse), 243
- Depot-medroxyprogesterone acetate, risk of cervical dysplasia, 443
- Dexamethasone, effect on implantation and embryo development (rat), 581
- Discontinuation, TCu 380A, 339
- dl-15-methyl PGF_{2α}, 501
- Drug interactions, use of progestin-only pills, S105
- Ectopic pregnancy, relationship to use of contraceptive, 253
- Effective use guidelines, progestin-only pills, S151
- Efficacy, progestin-only pills, S34
- Embryo development, effect of dexamethasone (rat), 581
- Endometrium, effect of levonorgestrel, 477
- Estradiol patches + vaginal ring releasing levonorgestrel, 87
- Estradiol valerate + norethisterone enanthate, 329
- Estrogen-progestagen, postcoital contraceptive, 101
- Estrogens, postcoital contraceptive, 101
- Ethinylestradiol + cyproterone acetate, 373
- Ethinyl estradiol + desogestrel, 153, 201, 301, 373
- Ethinyl estradiol + gestodene, 201, 301
- Ethinylestradiol + levonorgestrel, 563
- Ethinyl estradiol + norethindrone acetate, contraceptive vaginal ring, 517, 535
- Fertility, influence of midtrimester abortion, 239
- Fertility control methods,
 - benefits and risks, 1
 - modern vs traditional, 363

- Gallbladder disease and OC use, 167
 Gemeprost, 69
 Gossypol, effect on biochemical parameters (rat), 391
- Hormonal contraceptives, blood pressure changes, 131
 Husband counseling, effect on NORPLANT® implants acceptability, 263
 Hypertension, effect of mestranol (rat), 383
- Immunohistochemical staining in endometrium, effect of levonorgestrel, 477
 Implantation, effect of dexamethasone (rat), 581
 Infant development, progestogen-only contraceptives use during lactation, 55
 Infant growth, progestogen-only contraceptives use during lactation, 35
 Injectable contraceptive, estradiol valerate + norethisterone enanthate, 329
 Intrauterine device (IUD),
 benefits and risks, 1
 TCu 220C, 417
 TCu 380A, 17, 339, 417
 use as postcoital contraceptive, 101
 IUD (intrauterine device)
 IUD insertion, effect of antibiotics, 319
 IUD/OC use, improving quality of services, 215
- Laboratory test interactions, use of progestin-only pills, S105
 Lactation, use of progestogen-only contraceptives, 35, 55
 Laparoscopic sterilization, use of single/multiple clips, 409
 Lea's Shield®, barrier contraceptive, 551
 Levonorgestrel,
 postcoital contraceptive, 101
 Levonorgestrel-releasing vaginal ring, 87
 Long-interval use (9-week on, 1-week off), ethinyl estradiol + desogestrel, 153
- Male contraceptive method, prolactin injection (dog), 191
 Mammary growth pattern, effect of OC formulations (mouse), 175
- Marine red algae, postcoital contraceptive activity (rat), 291
 Medical considerations, use of progestin-only pills, S89
 Mestranol, effect on hypertension (rat), 383
 Metabolic effects, progestin-only pills, S53
 Metabolism, ST 1435 (Nestorone®), 275
 Methotrexate + misoprostol, 511
 Midtrimester abortion, influence on subsequent fertility, 239
 Mifepristone (RU 486)
 Misoprostol, 69, 501, 511
 Mode of action, progestin-only pills, S13
 Modern vs traditional fertility control methods, 363
 Monthly combined injectable contraception, 329
 Multiple/single clips, tubal sterilization, 409
- Neem seeds extract, spermicidal activity, 185
 Nestorone® (ST 1435), metabolism, 275
 Nonoxynol-9, spermicidal activity, 185
 NORPLANT® implants, 27, 109, 263, 349, 477
 NORPLANT® implants acceptability, effect of husband counseling, 263
 NORPLANT® II rods implants, 27
- OC (oral contraceptive)
 OC formulations, effect on mammary growth pattern (mouse), 175
 OC use and benign gallbladder disease, 167
 OC/IUD use, improving quality of services, 215
- Oral contraceptive (OC),
 benefits and risks, 1
 ethinylestradiol + cyproterone acetate, 373
 ethinyl estradiol + desogestrel, 153, 201, 301, 373
 ethinyl estradiol + gestodene, 201, 301
 ethinylestradiol + levonorgestrel, 563
 progestin-only, S9
 Ovarian function, following childbirth, 401
 Pharmacokinetics,
 ethinylestradiol + levonorgestrel, 563
 gestodene, 301

- 3-ketodesogestrel, 301
- Pharmacology, progestin-only pills, S22
- Postcoital contraception, review, 101
- Postcoital contraceptive activity, marine red algae (rat), 291
- Pregnancy outcomes, progestin-only pills, S34
- Pregnancy termination,
 - methotrexate + misoprostol, 511
 - RU 486 + dl-15-methyl PGF_{2α}, 501
 - RU 486 + gemeprost, 69
 - RU 486 + misoprostol, 69, 501
- Progestin-only oral contraception, review, December 1994 Supplement
- Progestin-only pills, usage, S9
- Progestin-only contraceptives during lactation, 35, 55
- Prolactin injection, male contraceptive method (dog), 191
- Quality of services, improved utilization of IUD/OC use, 215
- Quinacrine and copper, antineoplastic activity (mouse), 243
- Quinine hydrochloride, spermicidal activity, 185
- Recovery of ovarian function, following childbirth, 401
- Reetha saponins, spermicidal activity, 185
- Risk-benefit analysis, fertility control methods, 1
 - RU 486 (mifepristone), effect on cervix, 461
 - postcoital contraceptive, 101
 - RU 486 + dl-15-methyl PGF_{2α}, 501
 - RU 486 + gemeprost, 69
 - RU 486 + misoprostol, 69, 501
- Side effects, progestin-only pills, S114
- Slippage and breakage, condoms, 117
- ST 1435 (Nestorone[®]), 275
- Sterilization, use of single/multiple clips, 409
- Subdermal implants, levonorgestrel, 27, 109, 263, 349, 477
- TCu 220C, 417
- TCu 380A, 17, 339, 417
- Teenage contraceptive clinic, impact on conceptions, 77
- Testicular function, effect of vasectomy (rabbit), 491
- Traditional vs modern fertility control methods, 363
- Transdermal estradiol + vaginal ring releasing levonorgestrel, 87
- Tri-step OC, ethinylestradiol + levonorgestrel, 563
- Tubal ligation, benefits and risks, 1
- Tubal occlusion, single/multiple clips, 409
- Vaginal ring, releasing ethinyl estradiol + norethindrone acetate, 517, 535
- Vaginal ring, releasing levonorgestrel, 87
- Vasectomy,
 - benefits and risks, 1
 - effect on testicular function (rabbit), 491
- Vasovasostomy, effect on testicular function (rabbit), 491